Skip to content

Advertisement

BMC Infectious Diseases

Research article
Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model

  • Laith Yakob1Email author,
  • Thomas V Riley2,
  • David L Paterson3 and
  • Archie CA Clements1
BMC Infectious Diseases201313:376

https://doi.org/10.1186/1471-2334-13-376

©  Yakob et al.; licensee BioMed Central Ltd. 2013

Received: 18 March 2013

Accepted: 13 August 2013

Published: 16 August 2013

Open Peer Review reports

Abstract

Background

Clostridium difficile is the leading cause of infectious diarrhea in hospitalized patients. Its epidemiology has shifted in recent years from almost exclusively infecting elderly patients in whom the gut microbiota has been disturbed by antimicrobials, to now also infecting individuals of all age groups with no recent antimicrobial use.

Methods

A stochastic mathematical model was constructed to simulate the modern epidemiology of C. difficile in a healthcare setting, and, to compare the efficacies of interventions.

Results

Both the rate of colonization and the incidence of symptomatic disease in hospital inpatients were insensitive to antimicrobial stewardship and to the prescription of probiotics to expedite healthy gut microbiota recovery, suggesting these to be ineffective interventions to limit transmission. Comparatively, improving hygiene and sanitation and reducing average length of stay more effectively reduced infection rates. Although the majority of new colonization events are a result of within-hospital ward exposure, simulations demonstrate the importance of imported cases with new admissions.

Conclusions

By analyzing a wide range of screening sensitivities, we identify a previously ignored source of pathogen importation: although capturing all asymptomatic as well as symptomatic introductions, individuals who are exposed but not yet colonized will be missed by even a perfectly sensitive screen on admission. Empirical studies to measure the duration of this latent period of infection will be critical to assessing C. difficile control strategies. Moreover, identifying the extent to which the exposed category of individual contributes to pathogen importation should be explicitly considered for all infections relevant to healthcare settings.

Keywords

Symptomatic DiseaseClostridium DifficileHealthcare SettingBasic Reproduction NumberAntimicrobial Stewardship

Background

Clostridium difficile is a Gram-positive, toxin-producing anaerobic bacterium. Worldwide, it is the leading cause of infectious diarrhea in hospitalized patients. The incidence and severity of C. difficile infection (CDI) varies considerably among studied populations but the general trend shows an increase in recent decades [1–3], with a higher proportion of CDI patients undergoing colectomy and dying [4, 5]. The disease is currently estimated to cost $800 million per year in US acute care facilities [6]. Previously, persistently disturbed intestinal microbiota, usually as a result of antimicrobials, was considered a prerequisite of the disease. However, recent studies have demonstrated severe cases occurring in groups that were previously assumed to be low-risk, including pregnant women, children and people with no recent exposure to antimicrobials [7, 8], indicating either a changing epidemiology or more testing in these groups [9].

There is increasing evidence for a potentially important role of asymptomatic carriage in the epidemiology of CDI [10], with increasing rates recorded within healthcare settings [11] and for the wider community [12, 13]. Hospital rooms occupied by asymptomatic patients can have very high rates of contamination (29%) [14]. The dissociation between symptoms and infectivity was recently corroborated by a prospective clinical study in which 60% of patients still had skin contamination following resolution of diarrhea in CDI patients, and 37% continued to shed spores in their stool [15]. Carriers have been implicated in the global spread of hyper-virulent strains such as ribotype 027 which is believed to have caused over 2000 fatalities during the 2003–4 outbreak in Quebec, Canada [16]. Increased incidence, severity of disease associated with endemic strains and frequency of outbreaks emphasize the urgency for improved epidemiological understanding. To this end, we construct the most comprehensive epidemiological model of CDI transmission reported to date and use it to compare the efficacies of key interventions.

Surprisingly, there are only three modeling studies describing the mechanism of CDI transmission, each providing insight but with important limitations. The first mathematical model of CDI by Starr and colleagues [17] ignored asymptomatic carriage, a major potential source of infection for this disease [11, 18]. While this omission was rectified by the authors in a subsequent study [19], differential rates of progression to symptomatic disease between patients who were and who were not taking antimicrobials [20] were not accounted for. The third modeling study [21], developed by Lanzas and colleagues, did not allow for symptomatic disease in patients who were not on antimicrobials thereby overlooking a growing body of research showing high incidence rates in previously healthy individuals to be a key feature of C. difficile epidemiology [22, 23]. Although parsimony should always be a goal of epidemiological models, the inclusion of greater biological realism in our simulations highlights a hitherto unreported and potentially significant source of infection. We use this stochastic model to assess and compare the efficacies of several interventions to reduce infection transmission. We discuss the significance of our findings to infectious disease transmission within healthcare settings in general as well as specifically to the epidemiology of CDI.

Methods

The C. difficilepathogen

C. difficile is transmitted via the fecal-oral route. The infectious dose is small and the bacterium is capable of producing spores which can remain viable for years in the environment [24]. There has been a recent suggestion of inhalation of spores potentially providing a secondary mode of transmission [25, 26], but this is unlikely to contribute significantly to the disease’s epidemiology. On ingestion, the pathogen colonizes the gut and the host typically sheds bacteria in their stool within two weeks.

A significant proportion of infections is asymptomatic, with a spectrum of symptoms of varying severity experienced by the remainder [14, 27]. These symptoms include diarrhea, fever and abdominal pain and can result in toxic megacolon and death. Reasons for the development of symptomatic infection are incompletely understood but the risk factor most commonly associated with this progression is the disruption of normal gut microbiota by antimicrobials [28]. As a consequence of disrupted gut microbiota and lack of local immunity, the treatment of symptomatic infection with antimicrobials is met with high relapse rates in patients who do not successfully clear infection, as well as high reinfection rates [29]. Our model is the first that allows for treated individuals to return back to asymptomatically infected, exposed or uncolonized states to reflect the fact that treatment success is so variable. Following recent evidence of an increasing trend in colonization and disease in individuals who have not recently received antimicrobials [8], our model allows for the development of CDI without antibiotic involvement.

Epidemiological model parameterization

Patients in a hospital with 1000 beds were simulated for 1 year. Individuals were stratified according to infection status (Unexposed, Exposed, Colonized or Diseased) and whether or not they were currently taking antimicrobials (or had taken antimicrobials within the last 3 months). Exposed, colonized and diseased patients all harbor the pathogen; colonized and diseased patients contribute to transmission, but only diseased patients exhibit symptoms. The overall structure of the model is described in Figure 1. One novel component of our study is the incorporation of an ‘Exposed’ class of individuals which explicitly allows for the fact that individuals who are not colonized on admission may subsequently become colonized regardless of within-hospital exposure. The epidemiological consequences of this addition are discussed fully after the analysis.
Figure 1
Figure 1

Compartmental design of epidemiological model for Clostridium difficile. Individuals are either ‘U’nexposed, ‘E’xposed, ‘C’olonized or ‘D’iseased and are increasingly ‘vul’nerable when they have taken antimicrobials (‘Ab’). Patients of all epidemiological states can be admitted but only discharged if not symptomatic.

Average length of stay was assumed to be 6 days, reflecting rates that are typical of the US, Europe and Australia [30]. Patients could be admitted in any of the seven possible states but only discharged if they were not suffering from symptomatic disease. The proportion of new admissions that was taking (or had recently taken) antimicrobials was assumed to be 25% and the rates of antimicrobial prescription assumed that 50% of the hospital inpatients were currently on antimicrobials (or had taken them in the previous 3 months) [31, 32]. Recovery of gut microbiota following cessation of antimicrobial treatment was assumed to take 3 months [33]. New admissions were assumed to perfectly balance discharges, resulting in a constant population size that experienced frequency-dependent transmission. This is typical for the epidemiological modeling of human infectious diseases [34].

After a period of 5 days, exposed individuals became asymptomatically colonized [35]. For patients on antimicrobials, progression to symptomatic disease took a further 5 days [20]. Patients not on antimicrobials were assumed to be five-times less likely to progress to symptomatic disease [20]. Cure rate following treatment, which took 10 days [36], was assumed to be 80% [37], with the remaining treated patients returning to the exposed category. The symptoms of 33% of patients with CDI self-resolved [38] and 2% of symptomatic CDI patients died [20]. Table 1 summarizes the model parameters and definitions with associated cited studies.
Table 1

Epidemiological model symbology and parameterization

Parameter

Definition

Value (,Vul)

Reference

λ

Recovery of gut microbiota (day-1)

0.011

33

α

Antibiotic treatment (day-1)

0.11

31,32

β

Exposure (day-1)

Full range SIM

 

η

Dev into asympt infectious (day-1)

0.2,0.2

35

θ

Dev symptomatic CDI (day-1)

0.04,0.2

20

ρ

CDI treatment (day-1)

0.1

36

σ

Treatment failure (prop.)

0.2

37

ζ

Self-resolving symptoms (prop.)

0.33

38

μ

CDI case fatality rate (prop.)

0.02

20

κ

Hospital discharge (day-1)

0.17

30

ϵ

Hospital admission (proportion)

0.75,0.25

31,32

Q

Quarantined CDI ‘0’ yes, ‘1’ no

n/a

 

Mathematical model construction

Ordinary differential equations were constructed to reflect the biology of infection as parsimoniously as possible (Additional file 1). Traditionally, the basic reproduction number, R0, is used to estimate transmission potential of an infectious disease. R0 is a useful metric for estimating outbreak thresholds and is therefore of relevance in estimating risk of epidemic strains introduced into fully susceptible (disease-free) populations. The stable endemicity of C. difficile within healthcare settings represents a significant departure from a disease-free population. Moreover, R0 no longer quantifies risk nor discriminates between high levels and low levels of transmission when constant imports of pathogen are accounted for in healthcare settings [39]. Therefore, we present our results of control simulations in terms of the incidence of symptomatic disease and the ratio of colonized patients discharged from hospital relative to patients colonized on admission. An advantage of these measures of intervention efficacy is that they can be directly measured.

Because the simulated population is small, infection dynamics are more likely to be governed by stochastic processes. Therefore, the ordinary differential equations were converted into a stochastic simulation system based on Gillespie’s direct method [40]. This method of simulation accounts for continuous time but discrete state space whereby the probability of conversion from one state (e.g., Exposed) to another (e.g., Colonized) is determined by the associate rate of the ordinary differential equation system. There are 15 possible epidemiological state transitions in this system and they are summarized in Table 2. The table shows the transfer of individuals from one epidemiological compartment (“-1”) to another (“+1”).
Table 2

Epidemiological state transitions of the event-driven, stochastic model

Event

Transition probability

State change

Antibiotic treatment of uncolonized individual

αUδt

U-1, U v +1

          exposed individual

αEδt

E-1, E v +1

          colonized individual

αCδt

C-1, C v +1

Gut microbiota recovery of uncolonized individual

λU v δt

U v -1, U+1

            exposed individual

λE v δt

E v -1, E+1

            colonized individual

λC v δt

C v -1, C+1

Exposure of individual without recent Ab use

β[(C+C v +DQ)U/N]δt

U-1, E+1

      individual with recent Ab use

β[(C+C v +DQ)U v /N]δt

U v -1, E v +1

Colonization of individual without recent Ab use

ηEδt

E-1, C+1

       individual with recent Ab use

ηE v δt

E v -1, C v +1

Symptoms develop in indiv. without recent Ab use

θCδt

C-1, D+1

          individual with recent Ab use

θ v Cvδt

C v -1, D+1

Symptoms resolve

ζDδt

D-1, C v +1

Full clearance following treatment

(1-σ)ρDδt

D-1, U v +1

Treatment does not result in full clearance

σρDδt

D-1, E v +1

This stochastic model was used to compare the efficacy of four different control measures in reducing the rate of colonization within the hospital as well as the incidence of symptomatic CDI. These controls were 1) reducing the rate of antimicrobial prescription in order to minimize the proportion of patients with heightened vulnerability to symptomatic disease, 2) reducing the level of environmental contamination and improving hand hygiene, 3) administering probiotics to expedite the restoration of healthy gut microbiota, and, 4) the reduction of average length of stay of inpatients.

The importance of asymptomatic patients in infection transmission is a topic that has received a lot of recent interest [10, 11, 41, 42]. Despite this, the incubation periods for C. difficile are less well defined than for other pathogens [9]. Simulating infection dynamics across a wide range of incubation periods, we assessed the applicability of screening for asymptomatic, as well as symptomatic, admissions. Recent developments in commercially-available PCR screening technology have provided a sensitive (~90%) tool for rapidly detecting (~2 h) colonization with C. difficile[43]. Therefore, we gauged the utility of this screen as a further method of intervention under the assumption that hospitals have the facilities to segregate colonized (both asymptomatic and symptomatic) and non-colonized patients.

Results and discussion

The temporal output from a typical stochastic simulation run, using baseline parameterization and in the absence of intervention is shown in Figure 2. The top panel shows the percentage of colonized individuals discharged compared with the percentage of colonized admissions. Average colonization prevalence on admission was 4.0% (st. dev. 2.0) which closely matches a recent Canadian study that measured asymptomatic admission prevalence of 4.4% in 6 hospitals in Quebec 2006–2007 [20]. We could not find clinical studies measuring the prevalence of colonization on discharge to directly corroborate our simulated values. However, in our study, colonization and length of stay are independent variables and so prevalence in discharged patients is representative of inpatient prevalence. Hospital inpatient prevalence of endemic C. difficile varies a great deal over time and between different locations, but our average colonization prevalence of 30% (st. dev. 5.6%) falls within the range described in the clinical literature [44].
Figure 2
Figure 2

A typical simulation using baseline model parameterization. Subplots show the percentage of Clostridium difficile colonized patients who are admitted and discharged (top), the incidence of symptomatic disease (middle) and the proportional distribution of inpatient infection status (bottom). Stochastic (Direct Gillespie algorithm) simulations are run for a hospital with 1000 beds whereby newly admitted patients perfectly balance discharged individuals.

The middle panel of Figure 2 shows the incidence of symptomatic C. difficile infection which averages 2.8 cases per 1000 hospital bed days (st. dev. 4.2), also within the range described in the most comprehensive pan-European survey [45]. The very high rates of underreporting that are known to occur for this pathogen, especially in younger patients who have less severe symptoms, suggest that the true prevalence of infection lies towards the top-end of estimates [46]. The bottom panel shows the proportional distribution of the epidemiological states of hospital inpatients in which the ratio of total (vulnerable or otherwise) Unexposed: Exposed: Colonized: Diseased patients is 0.45: 0.26: 0.24: 0.05. Importantly, our baseline parameterization using the most up-to-date data available for this pathogen suggests that there are as many individuals in the ‘Exposed’ category as in the ‘Colonized’ category.

Figure 3 shows the sensitivity of two different outputs (ratio of colonized patients discharged compared with on admission, and, the incidence of symptomatic CDI), to the four model parameters pertaining to control – namely, the rate of antimicrobial prescription, the transmission coefficient (reduced by improved hygiene and sanitation), gut microbiota recovery rate (expedited with probiotics) and average length of stay. Projections from the model reinforce the clinical evidence supporting a reduced length of stay [47, 48] and infection control [49–51] as effective methods for attenuating the spread of C. difficile. While there is reassuring agreement between our model projections and clinical records of intervention efficacy, there is also an important disparity worth noting. Several recent studies have suggested antimicrobial stewardship to be an effective method of reducing the rate of CDI in hospitals [52–55]. However, these include studies that examined stewardship in conjunction with infection control procedures [54, 55], thereby obscuring the efficacy of reduced prescription rates alone. They also include studies that found either borderline significant reduction in CDI (P=0.04, [53]) or no statistical significance through a reduction in either high-risk drugs or total antimicrobial usage in healthcare settings (respectively, P=0.0597 and P=0.0823, [52]). Therefore, the conflicting evidence for CDI reduction through antimicrobial stewardship is in keeping with a small effect size, as demonstrated by our simulations.
Figure 3
Figure 3

The effects of different control measures on Clostridium difficile in the simulated hospital. The ratio of patients colonized with C. difficile when discharged compared to new admissions (left Y axis, points) are shown along with associated incidence of symptomatic disease per 1000 hospital bed days (right Y axis, crosses) across a wide range of the four tested control measures: reducing antimicrobial prescription (top-left), improved sanitation and hygiene (top-right), administering pro-biotics (bottom-left) and reducing the average length of stay (bottom-right). Each point is the average value of a 1-year simulation.

Infection rates were also insensitive to increased gut microbiota recovery promoted by probiotics. Cautious interpretation of this result is urged because while we found the overall influence that this treatment has on population-level transmission dynamics to be minimal, it does not necessarily negate the individual-level health benefits of probiotics.

Comparatively much greater returns were achieved by reducing the length of stay and through improved hygiene (respectively, bottom-right and top-right panel Figure 3). Halving the average inpatient length of stay yielded almost a 3-fold reduction in the colonized ratio of discharged compared with admitted patients. Additionally, a 10-fold decrease in CDI incidence was theoretically possible through improved hygiene and sanitation practices. However, even in this scenario whereby complete elimination of within-ward exposure was achieved (β=0), more patients left the hospital colonized than when they arrived. This is due to the expedited progression of disease resulting from antimicrobials, suggesting that stewardship might come into play as a more influential control tool once initial efforts have already eliminated ward-based transmission.

A thorough sensitivity analysis of model input parameters (see Additional file 2) demonstrates the robustness of our results pertaining to infection control. However, there are several limitations of this study that will require additional development and refinement. The life-course of the pathogen is incompletely understood. Our model structure assumes that all individuals who become symptomatic must first pass through a phase of shedding the pathogen asymptomatically. This follows on from the very comprehensive epidemiological study carried out by Loo and coauthors in which the time to developing symptomatic disease was measured to be twice that for developing asymptomatic colonization [20]. An alternative interpretation of this finding would be that the individuals who develop symptomatic infection never pass through a phase of asymptomatic shedding, but, instead, have a delayed progression of colonization. However, this would imply that successful colonization within patients that develop symptomatic disease is somehow delayed. In the absence of definitive evidence, therefore, our assumption seems more likely. Another limitation of the study is the assumption that asymptomatic shedders contribute equivalently to transmission as symptomatically infected individuals. While symptomatic disease involves a greater bacterial load, asymptomatic shedding would not prompt the same level of cautiousness in hygiene practices. Ascertaining the relative contributions of both category of individual will be a difficult, but important, issue to reconcile. Once good, reproducible data become available on this difference, the model can easily be adjusted to incorporate the additional information. A further limitation is the lack of consideration for healthcare professionals (and, also, hospital visitors) as vectors of infection – again, something that will require further development when the epidemiological data become available. Greater complexity can be iteratively incorporated into the framework presented here to explore additional risk factors including patient age as well as underlying co-morbidities and patient immune status. Future directions for this work also include assessing the integration of control tools. Integrated control has been strategized with mathematical models for a number of infectious diseases including sexually transmitted infections [56, 57], vector-borne diseases [58–60], newly emerging infections and pathogenic bioterrorism attacks [61, 62]. However, research into strategic combinations of healthcare-acquired infection control methods is underdeveloped.

Finally, we measured the sensitivity of the colonization ratio and the incidence of CDI on the pathogen’s incubation period – the C. difficile life history parameter of greatest uncertainty [9]. Intuitively, for shorter incubation periods, the colonization ratio increased along with CDI incidence (Figure 4). This is because longer incubation periods delay the rate at which a pathogen can spread between individuals. Remarkably, however, infection rates were extremely insensitive to screening sensitivity. Even where screening was 100% sensitive (current leading rapid screen sensitivity is ~90%) [43], little impact on infection rates was achieved by the segregation of all colonized admissions from non-colonized inpatients. Recent studies have suggested that a large proportion of patients colonized with C. difficile in healthcare settings was likely exposed to the pathogen before they were admitted [11, 21, 41, 42]. These authors thereby attribute a substantial role of asymptomatic individuals on the importation of infection. In this analysis, by screening and subsequently isolating both asymptomatic and symptomatic patients from the non-colonized inpatients, we have eliminated these sources of infection and uncovered a previously ignored and potentially important source of C. difficile in healthcare settings: new admissions who have been exposed to the pathogen but not yet colonized.
Figure 4
Figure 4

The effects of screening on Clostridium difficile in the simulated hospital. The ratio of patients that are colonized with C. difficile when discharged relative to on admission (left) are shown along with the associated incidence in symptomatic CDI per 1000 hospital bed days (right). Even highly sensitive screening (Y axis) can do little to impact either of these epidemiological outcomes. However, time to colonization (X axis), a component of the pathogen’s life course for which data is absent, is highly influential in its epidemiology.

Conclusions

Even a perfect screening test giving immediate results for all new admissions will fail to detect the carriage of C. difficile into the hospital by patients. Although obtaining good estimates of the incubation period has proven particularly difficult [9], it will be critical to uncovering the extent to which the exposed category of individuals influences the epidemiology of CDI. This finding is not only relevant to C. difficile epidemiology, but to any pathogen that can be undetectably transported by exposed individuals.

Declarations

Acknowledgements

The authors thank Camilla Wiuff and Jan Lindstrom for their useful comments. The study was supported by funding from the National Health and Medical Research Council of Australia, grant number APP1006243.

Authors’ Affiliations

(1)
School of Population Health, The University of Queensland, Brisbane, Australia
(2)
School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Australia
(3)
Centre for Clinical Research, The University of Queensland, Brisbane, Australia

References

  1. McDonald LC, Owings M, Jernigan DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006, 12 (3): 409-415. 10.3201/eid1203.051064.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Wilcox MH, Smyth ET: Incidence and impact of clostridium difficile infection in the UK, 1993–1996. J Hosp Infect. 1998, 39 (3): 181-187. 10.1016/S0195-6701(98)90256-0.View ArticlePubMedGoogle Scholar
  3. Lo Vecchio A, Zacur G: Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012, 28: 1-9. 10.1097/MOG.0b013e32834bc9a9.View ArticlePubMedGoogle Scholar
  4. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T, Croyle K, Krystofiak S, Patel-Brown S, et al: A large outbreak of clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005, 26 (3): 273-280. 10.1086/502539.View ArticlePubMedGoogle Scholar
  5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN: Increasing prevalence and severity of clostridium difficile colitis in hospitalized patients in the united states. Arch Surg. 2007, 142 (7): 624-631. 10.1001/archsurg.142.7.624.View ArticlePubMedGoogle Scholar
  6. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder RR, Lee BY: The economic burden of clostridium difficile. Clin Microbiol Infect. 2012, 18 (3): 282-289. 10.1111/j.1469-0691.2011.03571.x.View ArticlePubMedGoogle Scholar
  7. Benson L, Song X, Campos J, Singh N: Changing epidemiology of clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol. 2007, 28 (11): 1233-1235. 10.1086/520732.View ArticlePubMedGoogle Scholar
  8. Clements ACA, Magalhaes RJS, Tatem AJ, Paterson DL, Riley TV: Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010, 10 (6): 395-404. 10.1016/S1473-3099(10)70080-3.View ArticlePubMedGoogle Scholar
  9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH: Clinical practice guidelines for clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of america (IDSA). Infect Control Hosp Epidemiol. 2010, 31 (5): 431-455. 10.1086/651706.View ArticlePubMedGoogle Scholar
  10. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, Harrison LH: Use of MLVA genotyping to determine the role of asymptomatic carriers in C. Difficile transmission. Clin Infect Dis. 2013, 10.1093/cid/cit475. in pressGoogle Scholar
  11. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ: Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007, 45 (8): 992-998. 10.1086/521854.View ArticlePubMedGoogle Scholar
  12. Dial S, Delaney JAC, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired clostridium difficile-associated disease. JAMA. 2005, 294 (23): 2989-2995. 10.1001/jama.294.23.2989.View ArticlePubMedGoogle Scholar
  13. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ: Implications of the changing face of clostridium difficile disease for health care practitioners. Am J Infect Control. 2007, 35 (4): 237-253. 10.1016/j.ajic.2006.06.004.View ArticlePubMedGoogle Scholar
  14. McFarland LV, Mulligan ME, Kwok RY, Stamm WE: Nosocomial acquisition of clostridium difficile infection. N Engl J Med. 1989, 320 (4): 204-210. 10.1056/NEJM198901263200402.View ArticlePubMedGoogle Scholar
  15. Sethi A, Al‒Nassir W, Nerandzic M, Bobulsky G, Donskey C: Persistence of skin contamination and environmental shedding of clostridium difficile during and after treatment of C. Difficile infection. Infect Control Hosp Epidemiol. 2010, 31 (1): 21-27. 10.1086/649016.View ArticlePubMedGoogle Scholar
  16. Eggertson L: C. Difficile may have killed 2000 in quebec: study. Can Med Assoc J. 2005, 173 (9): 1020-1021. 10.1503/cmaj.051226.View ArticleGoogle Scholar
  17. Starr JM, Campbell A: Mathematical modeling of clostridium difficile infection. Clin Microbiol Infect. 2001, 7 (8): 432-437. 10.1046/j.1198-743x.2001.00291.x.View ArticlePubMedGoogle Scholar
  18. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN: Acquisition of clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992, 166 (3): 561-567. 10.1093/infdis/166.3.561.View ArticlePubMedGoogle Scholar
  19. Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ: Spatio-temporal stochastic modelling of clostridium difficile. J Hosp Infect. 2009, 71 (1): 49-56. 10.1016/j.jhin.2008.09.013.View ArticlePubMedGoogle Scholar
  20. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B, Beaudoin A, Frost EH, Gilca R, et al: Host and pathogen factors for clostridium difficile infection and colonization. N Engl J Med. 2011, 365 (18): 1693-1703. 10.1056/NEJMoa1012413.View ArticlePubMedGoogle Scholar
  21. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT: Epidemiological model for clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol. 2011, 32 (6): 553-561. 10.1086/660013.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH: The changing epidemiology of clostridium difficile infections. Clin Microbiol Rev. 2010, 23 (3): 529-549. 10.1128/CMR.00082-09.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Kelly CP, LaMont JT: Clostridium difficile–more difficult than ever. N Engl J Med. 2008, 359 (18): 1932-1940. 10.1056/NEJMra0707500.View ArticlePubMedGoogle Scholar
  24. Rupnik M, Wilcox MH, Gerding DN: Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009, 7 (7): 526-536. 10.1038/nrmicro2164.View ArticlePubMedGoogle Scholar
  25. Best EL, Fawley WN, Parnell P, Wilcox MH: The potential for airborne dispersal of clostridium difficile from symptomatic patients. Clin Infect Dis. 2010, 50 (11): 1450-1457. 10.1086/652648.View ArticlePubMedGoogle Scholar
  26. Roberts K, Smith CF, Snelling AM, Kerr KG, Banfield KR, Sleigh PA, Beggs CB: Aerial dissemination of clostridium difficile spores. BMC Infect Dis. 2008, 8: 7-7. 10.1186/1471-2334-8-7.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Kyne L, Merry C, O’Connell B, Kelly A, Keane C, O’Neill D: Factors associated with prolonged symptoms and severe disease due to clostridium difficile. Age Ageing. 1999, 28 (2): 107-113. 10.1093/ageing/28.2.107.View ArticlePubMedGoogle Scholar
  28. Bignardi GE: Risk factors for clostridium difficile infection. J Hosp Infect. 1998, 40 (1): 1-15. 10.1016/S0195-6701(98)90019-6.View ArticlePubMedGoogle Scholar
  29. Johnson S: Recurrent clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect. 2009, 58 (6): 403-410. 10.1016/j.jinf.2009.03.010.View ArticlePubMedGoogle Scholar
  30. OECD: Health at a Glance 2011: OECD Indicators. 2011, OECD Publishing, 10.1787/health_glance-2011-en.Google Scholar
  31. MacDougall C, Polk R: Variability in rates of Use of antibacterials among 130 US hospitals and risk‒adjustment models for interhospital comparison. Infect Control Hosp Epidemiol. 2008, 29: 203-211. 10.1086/528810.View ArticlePubMedGoogle Scholar
  32. Polk R, Fox C, Mahoney A, Letcavage JCM: Measurement of adult antibacterial drug Use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis. 2007, 44: 664-670. 10.1086/511640.View ArticlePubMedGoogle Scholar
  33. Rafii F, Sutherland J, Cerniglia C: Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag. 2008, 4: 1343-1358.PubMedPubMed CentralGoogle Scholar
  34. Keeling M, Rohani P: Modeling infectious diseases in humans and animals. 2007, Princeton, NJ: Princeton University PressGoogle Scholar
  35. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN: Nosocomial clostridium difficile colonisation and disease. Lancet. 1990, 336 (8707): 97-9100. 10.1016/0140-6736(90)91605-A.View ArticlePubMedGoogle Scholar
  36. McFarland LV: Update on the changing epidemiology of clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol. 2008, 5 (1): 40-48. 10.1038/ncpgasthep1029.View ArticlePubMedGoogle Scholar
  37. Leffler DA, Lamont JT: Treatment of clostridium difficile-associated disease. Gastroenterology. 2009, 136 (6): 1899-1912. 10.1053/j.gastro.2008.12.070.View ArticlePubMedGoogle Scholar
  38. Bartlett JG: Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis. 1984, 6 (suppl 1): S235-S241.View ArticlePubMedGoogle Scholar
  39. McBryde ES, Pettitt AN, McElwain DLS: A stochastic mathematical model of methicillin resistant staphylococcus aureus transmission in an intensive care unit: predicting the impact of interventions. J Theor Biol. 2007, 245 (3): 470-481. 10.1016/j.jtbi.2006.11.008.View ArticlePubMedGoogle Scholar
  40. Gillespie DT: Exact stochastic simulation of coupled chemical reactions. J Phys Chem. 1977, 81 (25): 2340-2361. 10.1021/j100540a008.View ArticleGoogle Scholar
  41. Muto CA, Blank MK, Marsh JW, Vergis EN, O’Leary MM, Shutt KA, Pasculle AW, Pokrywka M, Garcia JG, Posey K, et al: Control of an outbreak of infection with the hypervirulent clostridium difficile BI strain in a university hospital using a comprehensive “bundle” approach. Clin Infect Dis. 2007, 45 (10): 1266-1273. 10.1086/522654.View ArticlePubMedGoogle Scholar
  42. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O’Connor L, Griffiths D, Vaughan A, Finney J, Wilcox MH, et al: Characterisation of clostridium difficile hospital ward-based transmission using extensive epidemiological data and molecular typing. PLoS Med. 2012, 9 (2): e1001172-10.1371/journal.pmed.1001172.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Eastwood K, Else P, Charlett A, Wilcox M: Comparison of nine commercially available clostridium difficile toxin detection assays, a real-time PCR assay for C. Difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol. 2009, 47 (10): 3211-3217. 10.1128/JCM.01082-09.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Kyne L, Warny M, Qamar A, Kelly CP: Asymptomatic carriage of clostridium difficile and serum levels of IgG antibody against toxin a. N Engl J Med. 2000, 342 (6): 390-397. 10.1056/NEJM200002103420604.View ArticlePubMedGoogle Scholar
  45. Bauer MP, Kuijper EJ, van Dissel JT: European society of clinical microbiology and infectious diseases (ESCMID): treatment guidance document for clostridium difficile infection (CDI). Clin Microbiol Infect. 2009, 15 (12): 1067-1079. 10.1111/j.1469-0691.2009.03099.x.View ArticlePubMedGoogle Scholar
  46. Khanna S, Pardi D, Aronson S, Kammer P, Orenstein R, St Sauver J, Harmsen W, Zinsmeister A: The epidemiology of community-acquired clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012, 107: 89-95. 10.1038/ajg.2011.398.View ArticlePubMedGoogle Scholar
  47. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D: Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. Can Med Assoc J. 2004, 171 (1): 33-38. 10.1503/cmaj.1040876.View ArticleGoogle Scholar
  48. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault A-M, Nguyen T, Frenette C, Kelly M, et al: A predominantly clonal multi-institutional outbreak of clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med. 2005, 353 (23): 2442-2449. 10.1056/NEJMoa051639.View ArticlePubMedGoogle Scholar
  49. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J: Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995, 16: 459-477. 10.1086/648363.View ArticlePubMedGoogle Scholar
  50. Mayfield JL, Leet T, Miller J, Mundy LM: Environmental control to reduce transmission of clostridium difficile. Clin Infect Dis. 2000, 31: 995-1000. 10.1086/318149.View ArticlePubMedGoogle Scholar
  51. Thomas C, Stevenson M, Williamson DJ, Riley TV: Clostridium difficile-associated diarrhea: epidemiological data from western australia associated with a modified antibiotic policy. Clin Infect Dis. 2002, 35: 1457-1462. 10.1086/342691.View ArticlePubMedGoogle Scholar
  52. Aldeyab MA, Kearney MP, Scott MG, Aldiab MA, Alahmadi YM, Darwish Elhajji FW, Magee FA, McElnay JC: An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of clostridium difficile infection in hospital settings. J Antimicrob Chemother. 2012, 67 (12): 2988-2996. 10.1093/jac/dks330.View ArticlePubMedGoogle Scholar
  53. Jump RLPMDP, Olds DMRNP, Seifi NMS, Kypriotakis GMS, Jury LARNCNP, Peron EPP, Hirsch AAP, Drawz PEMD, Watts BMD, Bonomo RAMD, et al: Effective antimicrobial stewardship in a long-term care facility through an infectious disease consultation service: keeping a LID on antibiotic Use. Infect Control Hosp Epidemiol. 2012, 33 (12): 1185-1192. 10.1086/668429.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, Eastaway A, Seaton RA, Watson E, Gillies E, et al: Scottish antimicrobial prescribing group (SAPG): development and impact of the scottish national antimicrobial stewardship programme. Int J Antimicrob Agents. 2011, 38 (1): 16-26. 10.1016/j.ijantimicag.2011.02.005.View ArticlePubMedGoogle Scholar
  55. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J: Impact of a reduction in the Use of high-risk antibiotics on the course of an epidemic of clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007, 45 (2): S112-S121.View ArticlePubMedGoogle Scholar
  56. Anderson RM, Garnett GP: Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis. 2000, 27: 636-643. 10.1097/00007435-200011000-00012.View ArticlePubMedGoogle Scholar
  57. Nowak M, Anderson R, McLean A, Wolfs T, Goudsmit J, May R: Antigenic diversity thresholds and the development of AIDS. Science. 1991, 254: 963-969. 10.1126/science.1683006.View ArticlePubMedGoogle Scholar
  58. Yakob L, Clements ACA: A mathematical model of chikungunya dynamics and control: the major epidemic on réunion island. PLoS ONE. 2013, 8 (3): e57448-10.1371/journal.pone.0057448.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Yakob L, Dunning R, Yan G: Indoor residual spray and insecticide-treated bednets for malaria control: theoretical synergisms and antagonisms. J R Soc Interface. 2011, 8 (59): 799-806. 10.1098/rsif.2010.0537.View ArticlePubMedGoogle Scholar
  60. Yakob L, Yan G: Modeling the effects of integrating larval habitat source reduction and insecticide treated nets for malaria control. PLoS ONE. 2009, 4 (9): e6921-10.1371/journal.pone.0006921.View ArticlePubMedPubMed CentralGoogle Scholar
  61. Ferguson N, Keeling MJ, Edmunds WJ, Gani R, Brenfell BT, Anderson RM, Leach S: Planning for smallpox outbreaks. Nature. 1991, 425: 681-685.View ArticleGoogle Scholar
  62. Meyers LA: Contact network epidemiology: bond percolation applied to infectious disease prediction and control. Bull Am Math Soc. 2007, 44: 63-86.View ArticleGoogle Scholar

    63. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/13/376/prepub

Copyright

© Yakob et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

BMC Infectious Diseases

ISSN: 1471-2334

Contact us